IMMUNOLOGY2026™ Conference Recordings For Attendees-Intratumoral administration of a single dose of the HEPLISAV-B Vaccine and IL-15 complexes induces tumor regression in Triple Negative Brest Cancer

Intratumoral administration of a single dose of the HEPLISAV-B Vaccine and IL-15 complexes induces tumor regression in Triple Negative Brest Cancer

Back to course

Video Transcription

Video Summary

This presentation described a strategy to treat triple negative breast cancer (TNBC), an aggressive cancer with few targeted therapies, by reprogramming the tumor microenvironment using an intratumoral HEPLISAV-B hepatitis B vaccine, IL-15 complexes, and anti-PD-1 blockade. In a 4T1 mouse model, HEPLISAV-B alone caused tumor rejection in 3 of 5 mice and showed signs of tertiary lymphoid structure formation. Adding intratumoral IL-15 or anti-PD-1 improved responses but some tumors still relapsed. The full combination of HEPLISAV-B, IL-15, and anti-PD-1 led to 100% tumor-free survival with no recurrence through day 60. The speaker also noted changes in immune trafficking markers and evidence of immune cell organization within tumors. Overall, the study suggests that a repurposed FDA-approved vaccine can help convert “cold” TNBC tumors into active immune environments and may be a promising translational approach for future trials.

Meta Tag

Date April 16, 2026 10:45 AM - 11:00 AM

Room 157

Session Novel Tumor Therapies

Speaker Malia Leifheit

Track Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Year 2026

Keywords

triple negative breast cancer

HEPLISAV-B vaccine

tumor microenvironment reprogramming

IL-15 and anti-PD-1 therapy

tertiary lymphoid structures

April 16, 2026 10:45 AM - 11:00 AM

157

Novel Tumor Therapies

Malia Leifheit

Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

2026